The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
In vivo genome editing using Staphylococcus aureus Cas9
Open accessAbstract
The RNA-guided endonuclease Cas9 has emerged as a versatile genome-editing platform. However, the size of the commonly used Cas9 from Streptococcus pyogenes (SpCas9) limits its utility for basic research and therapeutic applications that use the highly versatile adeno-associated virus (AAV) delivery vehicle. Here, we characterize six smaller Cas9 orthologues and show that Cas9 from Staphylococcus aureus (SaCas9) can edit the genome with efficiencies similar to those of SpCas9, while being more than 1 kilobase shorter. We packaged SaCas9 and its single guide RNA expression cassette into a single AAV vector and targeted the cholesterol regulatory gene Pcsk9 in the mouse liver. Within one week of injection, we observed >40% gene modification, accompanied by significant reductions in serum Pcsk9 and total cholesterol levels. We further assess the genome-wide targeting specificity of SaCas9 and SpCas9 using BLESS, and demonstrate that SaCas9-mediated in vivo genome editing has the potential to be efficient and specific.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Also, the requirement of a specific PAM Sequence for targeted genome editing is crucial, and even though it reduces off-target activity, it often results in suboptimal DNA cleavage, editing efficiencies (Ran et al., 2015; Edraki et al., 2019) and restricting the scope of targeted edition.”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Ran et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cas9 genomic localization is delimited by the protospacer adjacent motif (PAM), which is NGG for SpCas9 while evolved variants of SpCas9 tolerate a broader range of PAM sequences17–21.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [20]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The SpCas9 homolog derived from Staphylococcus aureus (SaCas9) has been extensively characterized as a highly efficient and significantly smaller alternative to SpCas9.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“It recognizes an NNGRRT PAM (where R = A or G)20.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [20]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Recent advancements in gene-editing technologies have led to the development of artificial Cas9 variants with relaxed PAM specificities, which improve efficiency but are associated with an increase in off-target effects and a decrease in target specificity (Ran et al., 2015).”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Ran et al., 2015
Experimental — accuracy not yet measured
In the citing paper
“Recently, a smaller form of Cas9 was developed, and shown capable of packing and delivery with sgRNA by AAV in vivo12.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“Adenovirus or adeno-associated virus (AAV)-mediated CRISPR-Cas9 delivery has been successfully applied to knockout genes in the mouse brain and liver12,13.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“A smaller form of Cas9 (Staphylococcus aureus Cas9), which fits into AAV vectors, has been recently used to knockout genes by NHEJ in the mouse liver. More than 40% indel formations in Pcsk9 locus was reported12.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“For example, less than 10% indels at the Apob locus in the mouse liver was reported in the same study12.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“However, the large genetic size of Cas9 (~ 4.5 kb) and the total plasmid size (> 7 kb) significantly increase the difficulty of delivery and expression of CRISPR/Cas9 systems [94].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [94]
In the citing paper
“Although the newly discovered Cas9 form from Staphylococcus aureus strain (SaCas9) is about 1 kb shorter than SpCas9, the overall genetic size is still too large for application [94, 140].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [94]
In the citing paper
“The Cas9 from Staphylococcus aureus (SaCas9) is over 1 kb shorter (3.15 kb) than SpCas9 [69].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationMfold web server for nucleic acid folding and hybridization prediction
Zuker, M. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg595 · Cited by 13,404
WebLogo: A Sequence Logo Generator: Figure 1Preprint
Crooks, G. E., Hon, G. C., Chandonia, J., & Brenner, S. E. (2004) · Genome Research · doi:10.1101/gr.849004 · Cited by 12,418
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007) · Science · doi:10.1126/science.1138140 · Cited by 5,947
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Self-citationHigh-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,009
Ren, B., Liu, L., Li, S., Kuang, Y., Wang, J., Zhang, D., Zhou, X., Lin, H., & Zhou, H. (2019) · Molecular Plant · doi:10.1016/j.molp.2019.03.010 · Cited by 148
Delivery of CRISPR/Cas9 for therapeutic genome editing
Xu, X., Wan, T., Xin, H., Li, D., Pan, H., Wu, J., & Ping, Y. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3107 · Cited by 134
Towards application of CRISPR-Cas12a in the design of modern viral DNA detection tools (Review)
Dronina, J., Samukaitė-Bubnienė, U., & Ramanavičius, A. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01246-7 · Cited by 148
Burnight, E. R., Gupta, M., Wiley, L. A., Anfinson, K. R., Tran, A. A., Triboulet, R., Hoffmann, J. M., Klaahsen, D., Andorf, J. L., Jiao, C., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.015 · Cited by 153
Ohmori, T., Nagao, Y., Mizukami, H., Sakata, A., Muramatsu, S., Ozawa, K., Tominaga, S., Hanazono, Y., Nishimura, S., Nureki, O., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04625-5 · Cited by 144
A compact Cas9 ortholog from Staphylococcus Auricularis (SauriCas9) expands the DNA targeting scope
Hu, Z., Wang, S., Zhang, C., Gao, N., Li, M., Wang, D., Wang, D., Liu, D., Liu, H., Ong, S., et al. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000686 · Cited by 144
CRISPR-Cas-mediated transcriptional modulation: The therapeutic promises of CRISPRa and CRISPRi
Bendixen, L., Jensen, T. I., & Bak, R. O. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.03.024 · Cited by 150
CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo—Brief Report
Wang, X., Raghavan, A., Chen, T., Qiao, L., Zhang, Y., Ding, Q., & Musunuru, K. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307227 · Cited by 146
Transgenic mice for in vivo epigenome editing with CRISPR-based systems
Gemberling, M. P., Siklenka, K., Rodriguez, E., Eisinger, K. R. T., Barrera, A., Liu, F., Kantor, A., Li, L., Cigliola, V., Hazlett, M. F., et al. (2021) · Nature Methods · doi:10.1038/s41592-021-01207-2 · Cited by 155
Genome Engineering in Rice Using Cas9 Variants that Recognize NG PAM Sequences
Hua, K., Tao, X., Han, P., Wang, R., & Zhu, J. (2019) · Molecular Plant · doi:10.1016/j.molp.2019.03.009 · Cited by 143
Applications and developments of gene therapy drug delivery systems for genetic diseases
Pan, X., Veroniaina, H., Su, N., Sha, K., Jiang, F., Wu, Z., & Qi, X. (2021) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2021.05.003 · Cited by 149
The chemistry of Cas9 and its CRISPR colleagues
Chen, J. S., & Doudna, J. A. (2017) · Nature Reviews Chemistry · doi:10.1038/s41570-017-0078 · Cited by 143
Exploration of Plant-Microbe Interactions for Sustainable Agriculture in CRISPR Era
Shelake, R. M., Pramanik, D., & Kim, J. (2019) · Microorganisms · doi:10.3390/microorganisms7080269 · Cited by 147
Zhang, X., Chen, L., Zhu, B., Wang, L., Chen, C., Hong, M., Huang, Y., Li, H., Han, H., Cai, B., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0518-8 · Cited by 141
Novel vectors and approaches for gene therapy in liver diseases
Maestro, S., Weber, N. D., Zabaleta, N., Aldabe, R., & González‐Aseguinolaza, G. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100300 · Cited by 143
Current Progress in Therapeutic Gene Editing for Monogenic Diseases
Prakash, V., Moore, M., & Yáñez‐Muñoz, R. J. (2016) · Molecular Therapy · doi:10.1038/mt.2016.5 · Cited by 138
Zhao, X., Liu, L., Lang, J., Cheng, K., Wang, Y., Li, X., Shi, J. Y., Wang, Y., & Nie, G. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.042 · Cited by 139
Construct design for CRISPR/Cas-based genome editing in plants
Hassan, M. M., Zhang, Y., Yuan, G., De, K., Chen, J., Muchero, W., Tuskan, G. A., Qi, Y., & Yang, X. (2021) · Trends in Plant Science · doi:10.1016/j.tplants.2021.06.015 · Cited by 139
Long Terminal Repeat CRISPR-CAR-Coupled “Universal” T Cells Mediate Potent Anti-leukemic Effects
Georgiadis, C., Preece, R., Nickolay, L. E., Etuk, A., Petrova, A., Ładoń, D., Danyi, A., Humphryes-Kirilov, N., Ajetunmobi, A., Kim, D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.025 · Cited by 140
Hamilton, P. J., & Nestler, E. J. (2019) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2019.05.005 · Cited by 137
A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies
Razeghian, E., Nasution, M. K. M., Rahman, H. S., Gardanova, Z. R., Abdelbasset, W. K., Surendar, A., Bokov, D. O., Suksatan, W., Nakhaei, P., Shariatzadeh, S., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02510-7 · Cited by 147
CRISPR RNA-Dependent Binding and Cleavage of Endogenous RNAs by the Campylobacter jejuni Cas9
Dugar, G., Leenay, R. T., Eisenbart, S. K., Bischler, T., Aul, B. U., Beisel, C. L., & Sharma, C. M. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.01.032 · Cited by 144
Wei, T., Cheng, Q., Farbiak, L., Anderson, D. G., Langer, R., & Siegwart, D. J. (2020) · ACS Nano · doi:10.1021/acsnano.0c04707 · Cited by 143
Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing
Han, H. A., Pang, J. K. S., & Soh, B.-S. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01893-z · Cited by 134
Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9
LaFountaine, J. S., Fathe, K., & Smyth, H. D. C. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.08.029 · Cited by 111
Cebrian-Serrano, A., & Davies, B. (2017) · Mammalian Genome · doi:10.1007/s00335-017-9697-4 · Cited by 143
Zhang, D., Zhang, H., Li, T., Chen, K., Qiu, J., & Gao, C. (2017) · Genome biology · doi:10.1186/s13059-017-1325-9 · Cited by 133
Efficient inter-species conjugative transfer of a CRISPR nuclease for targeted bacterial killing
Hamilton, T. A., Pellegrino, G. M., Therrien, J. A., Ham, D. T., Bartlett, P. C., Karas, B. J., Gloor, G. B., & Edgell, D. R. (2019) · Nature Communications · doi:10.1038/s41467-019-12448-3 · Cited by 142
Highly specific targeted mutagenesis in plants using Staphylococcus aureus Cas9
Kaya, H., Mikami, M., Endo, A., Endo, M., & Toki, S. (2016) · Scientific Reports · doi:10.1038/srep26871 · Cited by 135
Massively parallel kinetic profiling of natural and engineered CRISPR nucleases
Jones, S. K., Hawkins, J. A., Johnson, N. V., Jung, C., Hu, K., Rybarski, J. R., Chen, J. S., Doudna, J. A., Press, W. H., & Finkelstein, I. J. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0646-5 · Cited by 131
Kumlehn, J., Pietralla, J., Hensel, G., Pacher, M., & Puchta, H. (2018) · Journal of Integrative Plant Biology · doi:10.1111/jipb.12734 · Cited by 142
Advances in CRISPR/Cas-based Gene Therapy in Human Genetic Diseases
Wu, S., Li, Q.-C., Yin, C., Xue, W., & Song, C. (2020) · Theranostics · doi:10.7150/thno.43360 · Cited by 145
CRISPR–Cas applications in agriculture and plant research
Tuncel, A., Pan, C., Clem, J. S., Liu, D., & Qi, Y. (2025) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-025-00834-3 · Cited by 145
CRISPR/Cas-based genome engineering in natural product discovery
Tong, Y., Weber, T., & Lee, S. Y. (2018) · Natural Product Reports · doi:10.1039/c8np00089a · Cited by 131
Impeding Transcription of Expanded Microsatellite Repeats by Deactivated Cas9
Pinto, B. S., Saxena, T., Oliveira, R., Méndez‐Gómez, H. R., Cleary, J. D., Denes, L. T., McConnell, O. L., Arboleda, J. D., Xia, G., Swanson, M. S., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.09.033 · Cited by 130
Genome editing: A perspective on the application of CRISPR/Cas9 to study human diseases (Review)
Rodríguez-Rodríguez, D. R., Ram�rez‐Sol�s, R., Garza‐Elizondo, M. A., Garza‐Rodr�guez, M., & Barrera-Saldaña, H. A. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4112 · Cited by 145
Self‐Assembled DNA Nanoclews for the Efficient Delivery of CRISPR–Cas9 for Genome Editing
Sun, W., Ji, W., Hall, J. M., Hu, Q., Wang, C., Beisel, C. L., & Gu, Z. (2015) · Angewandte Chemie · doi:10.1002/ange.201506030 · Cited by 132
Recent Advances in Genome Editing Using CRISPR/Cas9
Ding, Y., Li, H., Chen, L., & Xie, K. (2016) · Frontiers in Plant Science · doi:10.3389/fpls.2016.00703 · Cited by 144
Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression
Koo, T., Yoon, A. R., Cho, H., Bae, S., Yun, C., & Kim, J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx490 · Cited by 130
Implications of human genetic variation in CRISPR-based therapeutic genome editing
Scott, D. A., & Zhang, F. (2017) · Nature Medicine · doi:10.1038/nm.4377 · Cited by 129
Self-citationA Self-Deleting AAV-CRISPR System for In Vivo Genome Editing
Li, A., Lee, C. M., Hurley, A. E., Jarrett, K. E., Giorgi, M. D., Lu, W., Balderrama, K. S., Doerfler, A. M., Deshmukh, H., Ray, A., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.11.009 · Cited by 133
Chen, S., Sun, S., Moonen, D. P. I., Lee, C., Lee, A. Y.-F., Schaffer, D. V., & He, L. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.103 · Cited by 133
An engineered ScCas9 with broad PAM range and high specificity and activity
Chatterjee, P., Jakimo, N., Lee, J., Amrani, N., Rodríguez, T., Koseki, S., Tysinger, E., Qing, R., Hao, S., Sontheimer, E. J., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0517-0 · Cited by 131
Next Generation Prokaryotic Engineering: The CRISPR-Cas Toolkit
Mougiakos, I., Bosma, E. F., de Vos, W. M., van Kranenburg, R., & John van der, O. O. S. T. (2016) · Trends in biotechnology · doi:10.1016/j.tibtech.2016.02.004 · Cited by 137
Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells
Okada, M., Kanamori, M., Someya, K., Nakatsukasa, H., & Yoshimura, A. (2017) · Epigenetics & Chromatin · doi:10.1186/s13072-017-0129-1 · Cited by 129
Hurt, R. C., Buss, M. T., Duan, M., Wong, K., You, M. Y., Sawyer, D. P., Swift, M., Dutka, P., Barturen‐Larrea, P., Mittelstein, D. R., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01581-y · Cited by 125
Gene therapy and genome surgery in the retina
DiCarlo, J. E., Mahajan, V. B., & Tsang, S. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120429 · Cited by 127
Efficient delivery of nuclease proteins for genome editing in human stem cells and primary cells
Liu, J., Gaj, T., Yang, Y., Wang, N., Shui, S., Kim, S., Kanchiswamy, C. N., Kim, J., & Barbas, C. F. (2015) · Nature Protocols · doi:10.1038/nprot.2015.117 · Cited by 129
Synthetically controlling dendrimer flexibility improves delivery of large plasmid DNA
Kretzmann, J. A., Ho, D., Evans, C. W., Plani-Lam, J. H. C., García‐Bloj, B., Mohamed, A. E., O’Mara, M. L., Ford, E., Tan, D. E. K., Lister, R., et al. (2017) · Chemical Science · doi:10.1039/c7sc00097a · Cited by 129
Giannelli, S. G., Luoni, M., Castoldi, V., Massimino, L., Cabassi, T., Angeloni, D., Demontis, G. C., Leocani, L., Andreazzoli, M., & Broccoli, V. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx438 · Cited by 133
Exploration of CRISPR/Cas9-based gene editing as therapy for osteoarthritis
Zhao, L., Huang, J. H., Fan, Y., Li, J., You, T., He, S., Xiao, G., & Chen, D. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214724 · Cited by 127
Dead Cas Systems: Types, Principles, and Applications
Brezgin, S., Kostyusheva, A., Kostyushev, D. S., & Chulanov, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236041 · Cited by 135
Moreno, A. M., Palmer, N. D., Alemán, F., Chen, G., Pla, A., Jiang, N. J., Chew, W. L., Law, M., & Mali, P. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0431-2 · Cited by 132
Sun, W. D., Yang, J., Cheng, Z., Amrani, N., Liu, C., Wang, K., Ibraheim, R., Edraki, A., Huang, X., Wang, M., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.025 · Cited by 126
CRISPR/Cas9‐mediated genome editing: From basic research to translational medicine
Jacinto, F. V., Link, W., & Ferreira, B. I. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14916 · Cited by 135
The NIH Somatic Cell Genome Editing program
Saha, K., Sontheimer, E. J., Brooks, P. J., Dwinell, M. R., Gersbach, C. A., Liu, D. R., Murray, S. A., Tsai, S. Q., Wilson, R. C., Anderson, D. G., et al. (2021) · Nature · doi:10.1038/s41586-021-03191-1 · Cited by 127
Single-Stranded DNA Cleavage by Divergent CRISPR-Cas9 Enzymes
Ma, E., Harrington, L. B., O’Connell, M. R., Zhou, K., & Doudna, J. A. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.030 · Cited by 128
Expanding the CRISPR Toolbox in Zebrafish for Studying Development and Disease
Liu, K., Petree, C., Requena, T., Varshney, P., & Varshney, G. K. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00013 · Cited by 139
NmeCas9 is an intrinsically high-fidelity genome-editing platform
Amrani, N., Gao, X. D., Liu, P., Edraki, A., Mir, A., Ibraheim, R., Gupta, A., Sasaki, K. E., Wu, T., Donohoue, P. D., et al. (2018) · Genome biology · doi:10.1186/s13059-018-1591-1 · Cited by 128
AAV-mediated CRISPR/cas gene editing of retinal cells in vivo
Hung, S. S. C., Chrysostomou, V., Li, F., Lim, J. K. H., Wang, J.-H., Powell, J. E., Tu, L., Daniszewski, M., Lo, C., Wong, R. C., et al. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.16-19316 · Cited by 125
Scaffold-mediated CRISPR-Cas9 delivery system for acute myeloid leukemia therapy
Ho, T., Kim, H. S., Chen, Y., Li, Y., LaMere, M. W., Chen, C., Wang, H., Gong, J., Palumbo, C. D., Ashton, J. M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg3217 · Cited by 128
Zhou, X. X., Zou, X., Chung, H. K., Gao, Y., Liu, Y., Qi, L. S., & Lin, M. Z. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00603 · Cited by 125
Machine learning predicts new anti-CRISPR proteins
Eitzinger, S., Asif, A., Watters, K. E., Iavarone, A. T., Knott, G. J., Doudna, J. A., & Minhas, F. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa219 · Cited by 124
Engineering disease resistant plants through CRISPR-Cas9 technology
Tyagi, S., Kumar, R., Kumar, V., Won, S. Y., & Shukla, P. (2020) · GM crops & food · doi:10.1080/21645698.2020.1831729 · Cited by 129
Characterizing the activity of abundant, diverse and active CRISPR-Cas systems in lactobacilli
Crawley, A. B., Henriksen, E. D., Stout, E., Brandt, K., & Barrangou, R. (2018) · Scientific Reports · doi:10.1038/s41598-018-29746-3 · Cited by 119
Single-Cell Profiling of Ebola Virus Disease In Vivo Reveals Viral and Host Dynamics
Kotliar, D., Lin, A. E., Logue, J., Hughes, T. K., Khoury, N. M., Raju, S. S., Wadsworth, M. H., Chen, H. M., Kurtz, J. R., Dighero-Kemp, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.002 · Cited by 124
CRISPR/dCas9-Based Systems: Mechanisms and Applications in Plant Sciences
Karlson, C. K. S., Noor, S. N. M., Nolte, N., & Tan, B. C. (2021) · Plants · doi:10.3390/plants10102055 · Cited by 139
Lee, C. M., Cradick, T. J., Fine, E. J., & Bao, G. (2016) · Molecular Therapy · doi:10.1038/mt.2016.1 · Cited by 123
Applications of CRISPR-Cas Enzymes in Cancer Therapeutics and Detection
Huang, C., Lee, K.-C., & Doudna, J. A. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.05.006 · Cited by 119
Genome Engineering Using Adeno-associated Virus: Basic and Clinical Research Applications
Gaj, T., Epstein, B. E., & Schaffer, D. V. (2015) · Molecular Therapy · doi:10.1038/mt.2015.151 · Cited by 124
Harnessing CRISPR/Cas systems for programmable transcriptional and post-transcriptional regulation
Mahas, A., Neal Stewart, C., & Mahfouz, M. M. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2017.11.008 · Cited by 110
Meganuclease targeting of PCSK9 in macaque liver leads to stable reduction in serum cholesterol
Wang, L., Smith, J., Breton, C. A., Clark, P., Zhang, J., Lei, Y., Che, Y., Lape, J., Bell, P. L., Calcedo, R., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4182 · Cited by 119
Epigenome editing technologies for discovery and medicine
McCutcheon, S. R., Rohm, D., Iglesias, N., & Gersbach, C. A. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02320-1 · Cited by 130
Engineering Delivery Vehicles for Genome Editing
Nelson, C. E., & Gersbach, C. A. (2016) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-080615-034711 · Cited by 120
Genome editing by natural and engineered CRISPR-associated nucleases
Wu, W. Y., Lebbink, J. H. G., Kanaar, R., Geijsen, N., & John van der, O. O. S. T. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0080-x · Cited by 119
Lyu, P., Javidi-Parsijani, P., Atala, A., & Lu, B. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz605 · Cited by 123
A new age in functional genomics using CRISPR/Cas9 in arrayed library screening
Agrotis, A., & Ketteler, R. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00300 · Cited by 116
Miniature type V-F CRISPR-Cas nucleases enable targeted DNA modification in cells
Bigelyte, G., Young, J. K., Karvelis, T., Budre, K., Žedaveinytė, R., Djukanovic, V., Ginkel, E. V., Paulraj, S., Gasior, S. L., Jones, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26469-4 · Cited by 118
CRISPR Modeling and Correction of Cardiovascular Disease
Liu, N., & Olson, E. N. (2022) · Circulation Research · doi:10.1161/circresaha.122.320496 · Cited by 120
Neumann, E. N., Bertozzi, T. M., Wu, E., Serack, F. E., Harvey, J. W., Brauer, P. P., Pirtle, C. P., Coffey, A. A., Howard, M., Kamath, N., et al. (2024) · Science · doi:10.1126/science.ado7082 · Cited by 129
Paulsen, B. S., Mandal, P. K., Frock, R. L., Boyraz, B., Yadav, R., Upadhyayula, S., Gutierrez‐Martinez, P., Ebina, W., Fasth, A. L., Kirchhausen, T. L., et al. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0145-2 · Cited by 117
Wan, T. Y., Niu, D., Wu, C., Xu, F., Church, G. M., & Yuan, P. (2019) · Materials Today · doi:10.1016/j.mattod.2018.12.003 · Cited by 119
CRISPR/Cas9 gene drives in genetically variable and nonrandomly mating wild populations
Drury, D. W., Dapper, A. L., Siniard, D. J., Zentner, G. E., & Wade, M. J. (2017) · Science Advances · doi:10.1126/sciadv.1601910 · Cited by 116
Genome Editing: A New Approach to Human Therapeutics
Porteus, M. H. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124454 · Cited by 118
DNA-binding-domain fusions enhance the targeting range and precision of Cas9
Bolukbasi, M. F., Gupta, A., Oikemus, S., Derr, A. G., Garber, M. G., Brodsky, M. H., Zhu, L. J., & Wolfe, S. A. (2015) · Nature Methods · doi:10.1038/nmeth.3624 · Cited by 117
CRISPR/Cas9 Genome-Editing System in Human Stem Cells: Current Status and Future Prospects
Zhang, Z., Zhang, Y., Gao, F., Han, S., Cheah, K. S. E., Tse, H., & Lian, Q. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.09.009 · Cited by 122
Hybridization Kinetics Explains CRISPR-Cas Off-Targeting Rules
Klein, M., Eslami-Mossallam, B., Arroyo, D. G., & Depken, M. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.045 · Cited by 113
Genetic Modification for Wheat Improvement: From Transgenesis to Genome Editing
Borisjuk, N. V., Kishchenko, O., Eliby, S., Schramm, C., Anderson, P., Jatayev, S., Kurishbayev, A. K., & Shavrukov, Y. (2019) · BioMed Research International · doi:10.1155/2019/6216304 · Cited by 118
Nucleic acid nanoassembly-enhanced RNA therapeutics and diagnosis
Zhao, M., Wang, R., Yang, K., Jiang, Y., Peng, Y., Li, Y., Zhang, Z., Ding, J., & Shi, S. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.10.019 · Cited by 118
Zinc Fingers, TALEs, and CRISPR Systems: A Comparison of Tools for Epigenome Editing
Waryah, C. B., Moses, C., Arooj, M., & Blancafort, P. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7774-1_2 · Cited by 117
Precision cancer mouse models through genome editing with CRISPR-Cas9
Mou, H., Kennedy, Z., Anderson, D. G., Yin, H., & Xue, W. (2015) · Genome Medicine · doi:10.1186/s13073-015-0178-7 · Cited by 116
Genome engineering through CRISPR/Cas9 technology in the human germline and pluripotent stem cells
Vassena, R., Heindryckx, B., Peco, R., Pennings, G., Raya, Á., Sermon, K., & Veiga, A. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw005 · Cited by 117
Peptide/Cas9 nanostructures for ribonucleoprotein cell membrane transport and gene edition
Lostalé‐Seijo, I., Louzao, I., Juanes, M., & Montenegro, J. (2017) · Chemical Science · doi:10.1039/c7sc03918b · Cited by 115
All-in-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivo
Ibraheim, R., Song, C., Mir, A., Amrani, N., Xue, W., & Sontheimer, E. J. (2018) · Genome biology · doi:10.1186/s13059-018-1515-0 · Cited by 111
Engineering cell sensing and responses using a GPCR-coupled CRISPR-Cas system
Kipniss, N. H., Dingal, P. C. D. P., Abbott, T. R., Gao, Y., Wang, H., Dominguez, A. A., Labanieh, L., & Qi, L. S. (2017) · Nature Communications · doi:10.1038/s41467-017-02075-1 · Cited by 113
Hunker, A. C., Soden, M. E., Krayushkina, D., Heymann, G., Awatramani, R. B., & Zweifel, L. S. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.02.092 · Cited by 124
CRISPR-Cas12a delivery by DNA-mediated bioresponsive editing for cholesterol regulation
Sun, W., Wang, J., Hu, Q., Zhou, X., Khademhosseini, A., & Gu, Z. (2020) · Science Advances · doi:10.1126/sciadv.aba2983 · Cited by 115
Lu, Y., Cui, X., Zhang, L., Wang, X., Xu, Y., Qin, Z., Liu, G., Wang, Q., Tian, K., Lim, K. S., et al. (2022) · Aging and Disease · doi:10.14336/ad.2021.0929 · Cited by 117
Massively Parallel Biophysical Analysis of CRISPR-Cas Complexes on Next Generation Sequencing Chips
Jung, C., Hawkins, J. A., Jones, S. K., Xiao, Y., Rybarski, J. R., Dillard, K. E., Hussmann, J. A., Saifuddin, F. A., Savran, C. A., Ellington, A. D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.044 · Cited by 112
How specific is CRISPR/Cas9 really?
O’Geen, H., Yu, A. S., & Segal, D. J. (2015) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2015.10.001 · Cited by 108
Metadata
- Authors
- Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., Koonin, E. V., Sharp, P. A., & Zhang, F.
- Affiliations
- Broad Institute (US)
- Massachusetts Institute of Technology (US)
- Koch Institute for Integrative Cancer Research At MIT (US)
- National Institutes of Health (US)
- Corresponding author
- Zhang, Feng
- ORCID
- Venue
- Nature
- Published
- 2015-04
- Volume
- 520
- Issue
- 7546
- Pages
- 186-191
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4393360
- OpenAlex
- W2070614858
- Cited by
- 2,687
- References
- 51
- Citations by year
- 2026: 126 · 2025: 167 · 2024: 180 · 2023: 199 · 2022: 285 · 2021: 263 · 2020: 274 · 2019: 261 · 2018: 264 · 2017: 288 · 2016: 264 · 2015: 113
- FWCI
- 134.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- PMC
- Funders
- Howard Hughes Medical Institute
- National Institute of Mental Health (DP1MH100706)
- National Eye Institute (R01EY024259, P30EY012196)
- National Cancer Institute (R01CA133404, P01CA042063, P30CA014051, P30-CA-14051, P01 CA 42063)
- National Institute of General Medical Sciences (R01GM034277, T32GM008313, R01 GM34277, T32GM007753)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK097768)
- National Center for Chronic Disease Prevention and Health Promotion (5DP1-MH100706)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- SaCas9, SpCas9, CRISPR/Cas9, in vivo gene editing, adeno-associated virus delivery, PCSK9, cholesterol regulation, targeting specificity, single guide RNA
- MeSH terms
- Proprotein Convertase 9, Animals, Base Sequence, Cholesterol, Genetic Engineering, Liver, Male, Mice, Inbred C57BL, Serine Endopeptidases, Staphylococcus aureus, Substrate Specificity, Genome, Gene Targeting, Proprotein Convertases, Mice, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
